- About Us
- Our Story
- Our Products
- Our Science
- Our People
- Our Citizenship
-
Investors
- Reports and Filings
- Presentations
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Governance
- Investor Services
- Media
- Partners
- Canada
- Australia
- Germany
- India
- New Zealand
- China
- Netherlands
- Spain
- Contact Us
Press Releases
Dec
- Dr. Reddy’s announces the relaunch of Esomeprazole Magnesium Delayed-Release Capsules, USP
- Dr. Reddy’s promotes access to Community Health in Vizianagaram District
- Update on USFDA warning letter
- Dr. Reddy’s signs MoU with LSSSDC and VIPER to Strengthen the Skilled Labour Pool in the Life Science Industry
Nov
- Update on USFDA warning letter
- Dr. Reddy's issues clarification statement
- Dr. Reddy's announces the completion of Fondaparinux intellectual property purchase
- Statement from Dr. Reddy’s regarding the receipt of Temporary Restraining Order (TRO) for esomeprazole capsules
- Dr. Reddy’s statement on the receipt of Warning Letter from US FDA
- Biocodex inks distribution pact with Dr. Reddy’s to market its flagship products in Romania
- Dr. Reddy’s strengthens OTC portfolio - launches Nise D Spray
Sep
Aug
Jul
Jun
May
- Dr Reddy’s Laboratories Limited and AstraZeneca Pharma India Limited entered into a distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 Diabetes
- Dr. Reddy’s launches Somazina® for stroke patients in India
- Dr. Reddy’s Q4 FY15 Financial Results:Q4 FY15 Revenues at ₹38.7 billion, Q4 FY15 EBITDA at ₹8.1 billion
- Satish Reddy Appointed as National Safety Council Chairman
- Satish Reddy Appointed as National Safety Council Chairman
Apr
Mar
- Dr. Reddy’s Laboratories enters into partnership with Hetero to accelerate access to treatment for Hepatitis C in India
- Dr. Reddy’s and Nordion Inc. (formerly MDS Inc.) settle claims
- Dr. Reddy’s Custom Pharmaceutical Services Creates new Center of Excellence for Fully Integrated Formulation Development Services
